

1           **Healthcare workers with mild / asymptomatic SARS-CoV-2 infection show T cell**  
2           **responses and neutralising antibodies after the first wave**

3  
4  
5 Catherine J. Reynolds<sup>1,15</sup>, Leo Swadling<sup>2,15</sup>, Joseph M. Gibbons<sup>3,15</sup>, Corinna Pade<sup>3,15</sup>,  
6 Melanie P. Jensen<sup>4</sup>, Mariana O. Diniz<sup>2</sup>, Nathalie M. Schmidt<sup>2</sup>, David Butler<sup>1</sup>, Oliver E. Amin<sup>2</sup>,  
7 Sasha N. L. Bailey<sup>1</sup>, Stephen Taylor<sup>5</sup>, Jessica Jones<sup>5</sup>, Meleri Jones<sup>3,6</sup>, Wing-Yiu Jason Lee<sup>3</sup>,  
8 Joshua Rosenheim<sup>2</sup>, Aneesh Chandran<sup>2</sup>, George Joy<sup>4</sup>, Cecilia Di Genova<sup>7</sup>, Nigel  
9 Temperton<sup>7</sup>, Jonathan Lambourne<sup>8</sup>, Teresa Cutino-Moguel<sup>9</sup>, Mervyn Andiapen<sup>4</sup>, Marianna  
10 Fontana<sup>10</sup>, Angelique Smit<sup>10</sup>, Amanda Semper<sup>5</sup>, Ben O'Brien<sup>4,11,12</sup>, Benjamin Chain<sup>2</sup>, Tim  
11 Brooks<sup>5</sup>, Charlotte Manisty<sup>4,13</sup>, Thomas Treibel<sup>4,13</sup>, James C Moon<sup>4,13</sup>, COVIDsortium  
12 investigators, Mahdad Noursadeghi<sup>2</sup>, COVIDsortium immune correlates network, Daniel M.  
13 Altmann<sup>14,16</sup>, Mala K. Maini<sup>2,16</sup>, Aine McKnight<sup>3,16</sup>, Rosemary J. Boyton<sup>1,15,16,\*</sup>

14  
15  
16 <sup>15</sup>These authors contributed equally. <sup>16</sup>Joint senior authors

17 <sup>1</sup>Department of Infectious Disease, Imperial College London, London, UK

18 <sup>2</sup>Division of Infection and Immunity, University College London, London, UK

19 <sup>3</sup>Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary  
20 University of London, London, UK

21 <sup>4</sup>Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK

22 <sup>5</sup>National Infection Service, Public Health England, Porton Down, UK

23 <sup>6</sup>Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and  
24 Dentistry, Queen Mary University of London, London, UK

25 <sup>7</sup>Viral Pseudotype Unit, Medway School of Pharmacy, Chatham Maritime, Kent, UK

26 <sup>8</sup>Department of Infection, Barts Health NHS Trust, London, UK

27 <sup>9</sup>Department of Virology, Barts Health NHS Trust, London, UK

28 <sup>10</sup>Royal Free London NHS Foundation Trust, London, UK

29 <sup>11</sup>William Harvey Research Institute, Barts and the London School of Medicine and  
30 Dentistry, Queen Mary University of London, London, UK

31 <sup>12</sup>German Heart Centre and Charité University, Berlin, Germany

32 <sup>13</sup>Institute of Cardiovascular Science, University College London, UK.

33 <sup>14</sup>Department of Immunology and Inflammation, Imperial College London, London, UK

34 <sup>15</sup>Lung Division, Royal Brompton & Harefield NHS Foundation Trust, London, UK

35  
36  
37  
38  
39 \*Corresponding author

40 Prof. Rosemary Boyton, PhD, FRCP, FHEA

41 Professor of Immunology and Respiratory Medicine

42 Adult Infectious Disease, Department of Infectious Disease, Faculty of Medicine,

43 Room 8N22, Commonwealth Building, Hammersmith Hospital Campus

44 Imperial College London, Du Cane Road, London W12 0NN, UK.

45 Email: [r.boyton@imperial.ac.uk](mailto:r.boyton@imperial.ac.uk)

46 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

47 **Abstract**

48

49 Studies of adaptive immunity to SARS-CoV-2 include characterisation of lethal,  
50 severe and mild cases<sup>1-8</sup>. Understanding how long immunity lasts in people who  
51 have had mild or asymptomatic infection is crucial. Healthcare worker (HCW) cohorts  
52 exposed to and infected by SARS-CoV-2 during the early stages of the pandemic  
53 are an invaluable resource to study this question<sup>9-14</sup>. The UK COVIDsortium is a  
54 longitudinal, London hospital HCW cohort, followed from the time of UK lockdown<sup>9,10</sup>  
55 ; weekly PCR, serology and symptom diaries allowed capture of asymptomatic  
56 infection around the time of onset, so duration of immunity could be tracked. Here,  
57 we conduct a cross-sectional, case-control, sub-study of 136 HCW at 16-18 weeks  
58 after UK lockdown, with 76 having had laboratory-confirmed SARS-CoV-2 mild or  
59 asymptomatic infection. Neutralising antibodies (nAb) were present in 90% of  
60 infected HCW sampled after the first wave; titres, likely to correlate with functional  
61 protection, were present in 66% at 16-18 weeks. T cell responses tended to be lower  
62 in asymptomatic infected HCW than those reporting case-definition symptoms of  
63 COVID-19, while nAb titres were maintained irrespective of symptoms. T cell and  
64 antibody responses were discordant. HCW lacking nAb also showed undetectable T  
65 cells to Spike protein but had T cells of other specificities. Our findings suggest that  
66 the majority of HCW with mild or asymptomatic SARS-CoV-2 infection carry nAb  
67 complemented by multi-specific T cell responses for at least 4 months after mild or  
68 asymptomatic SARS-CoV-2 infection.

69 The majority of people infected by SARS-CoV-2 have not been hospitalised and lack  
70 PCR confirmation of infection. A key concern is the extent to which immunity in mild  
71 or asymptomatic cases may confer protection from future infection<sup>6,15-18</sup>. The UK  
72 COVIDsortium recruited a cohort of 731 HCW at three London hospitals early in the  
73 pandemic at the time of UK lockdown (23<sup>rd</sup> March 2020)<sup>9,10</sup>. HCW underwent  
74 longitudinal follow-up including weekly nasopharyngeal swabs for SARS-CoV-2  
75 PCR, serum collection for antibody analysis and a self-reporting health  
76 questionnaire. 21.5% had laboratory confirmed infection and all were asymptomatic  
77 or had mild disease. We conducted a cross-sectional case-controlled sub-study  
78 (n=136) to analyse T cell and nAb immunity at 16-18 weeks after UK lockdown  
79 (Extended Data Table 1a). We collected samples from 76 HCW with laboratory-  
80 defined evidence of SARS-CoV-2 infection and 60 HCW matched for age, gender  
81 and ethnicity that were consistently SARS-CoV-2 PCR negative and serology  
82 negative. Here, we set out to investigate whether asymptomatic or mild infection with  
83 SARS-CoV-2 would confer specific nAb and T cell responses lasting beyond 4  
84 months.

85

### 86 **SARS-CoV-2 multi-specific T cell response**

87 A number of T cell studies investigating SARS-CoV-2 infection have described the  
88 presence of Th1 immunity<sup>7</sup>. We assessed SARS-CoV-2 T cell frequencies by IFN $\gamma$ -  
89 ELISpot using three complementary approaches: whole protein<sup>1</sup>, mapped epitope  
90 peptide (MEP) pools<sup>4</sup>, and overlapping peptide (OLP) pools<sup>3</sup> (Extended Data Table  
91 2a, b). The use of whole protein allows assessment of CD4 T cell responses to  
92 naturally processed epitopes, whereas the MEP and OLP pools assessed a  
93 combination of CD4 and CD8 T cell responses directed against defined  
94 immunogenic regions and unbiased coverage of key viral proteins, respectively.

95

96 Analysing T cell responses to Spike and Nucleoprotein (NP) protein in HCW with  
97 mild or asymptomatic, laboratory confirmed infection, only 49% responded to Spike  
98 whereas significantly more (85%) responded to NP, showing a wide range of  
99 frequencies (Fig. 1a). Using MEP pools containing previously mapped immunogenic  
100 regions and offering good coverage for regional HLA genotypes<sup>4</sup>, responses of >80  
101 SFC/10<sup>6</sup> PBMC were found in 69% to peptide pools for Spike, NP, Membrane (M)

102 and open reading frame (ORF)3a/7a, with the latter being at a significantly lower  
103 frequency. Eighty-seven percent of HCW had detectable T cell responses to these  
104 MEP pools (Fig. 1b). A third T cell stimulation platform used OLP pools spanning the  
105 whole of NP, M, and ORF3a, together with 15mers spanning immunogenic regions  
106 of Spike (Extended Data Fig. 1a); using this approach, we assessed multi-specificity  
107 and cumulative SARS-CoV-2-specific T cell frequencies. This indicated a wide range  
108 of cumulative T cell response frequencies, from zero to >1000 SFC/10<sup>6</sup> PBMC, with  
109 86% showing a detectable T cell response (Fig. 1c). Of note with both the MEP and  
110 OLP platforms, responses to ORF3a/7a or ORF3a respectively were significantly  
111 lower than other antigens (Fig. 1b; Extended Data Fig. 1a). Although T cell  
112 responses to individual regions were relatively weak, their cumulative frequencies  
113 across all pools tested were similar in magnitude to that of T cells directed against a  
114 pool of well-described CD8 epitopes from influenza, EBV and CMV assessed in  
115 parallel in the same donors (Extended Data Fig. 1a), and comparable to frequencies  
116 found against SARS-CoV-1 pools following SARS infection<sup>19</sup>

117

118 Responses to Spike, NP protein and Spike, NP and M MEP were significantly higher  
119 frequency in HCW with laboratory confirmed SARS-CoV-2 infection than those in the  
120 matched group without laboratory evidence of infection (Fig.1d, Extended Data Fig.  
121 1, c-d). For example, 85% and 49% of HCW with laboratory confirmed SARS-CoV-2  
122 had T cell responses to NP and Spike protein respectively, compared with 29% and  
123 12% of SARS-CoV-2 PCR negative and S1 IgG negative HCW ( $p < 0.0001$ ) (Fig.1d).  
124 T cell recognition of these stimuli in HCW without evidence of infection, irrespective  
125 of reported COVID-19-like symptoms, was similar to that seen in pre-COVID-19  
126 pandemic controls (Fig. 1d, Extended Data Fig. 1c, d; Extended Data Table 1a, b).  
127 The OLP pools (utilising increased cell numbers) showed detectable T cell  
128 responses in the PCR negative, S1 IgG negative HCW group (Extended Data Fig.  
129 1b). With every T cell stimulation approach tested, responses were also seen in a  
130 proportion of pre-pandemic controls. Epitope mapping studies will be required to  
131 investigate possible cross-reactive components of these responses with other  
132 human coronaviruses as other studies have highlighted<sup>2,3,20</sup> and to assess the  
133 impact of any such cross-reactivity on disease outcome, whether positive or  
134 negative<sup>21,22</sup>.

135 In addition to IFN $\gamma$  SFC, we explored other cytokines indicative of non-Th1 subset  
136 polarisation by screening supernatants from Spike and NP protein-stimulated  
137 ELISpots; they showed no evidence of IL-4, 5, 13, 17 or 23 (Extended Data Fig. 1e).

138  
139 In line with previous observations of SARS-CoV-2 T cells and ageing<sup>23</sup>, T cell  
140 responses in HCW (n=75) with laboratory confirmed SARS-CoV-2 correlated with  
141 age. There was a correlation with increasing age and T cell responses against Spike  
142 MEP2, NP1 OLP and ORF3a/7a MEP (Extended Data Fig. 2a-d). Broken down by  
143 age and gender, T cell immunity to Spike increased with age in males (Spike protein;  
144  $r=0.522$ ,  $p=0.006$ ) (Extended Data Fig. 2e). We found no differences in T cell  
145 responses associated with ethnicity (Extended Data Fig. 3a,b). T cell immunity to M  
146 MEP, ORF3a/7a MEP and ORF3a OLP was higher in males compared to females  
147 (Extended data Fig. 3c,d).

148

#### 149 **Neutralising antibodies to SARS-CoV-2 at 16-18 weeks**

150 The majority of HCW in this cohort with laboratory confirmed SARS-CoV-2 infection  
151 had detectable S1 IgG and/or NP IgG/IgM (97%) during follow-up. Peak antibody  
152 level during 16-18 week follow-up (Fig2a) was considered to be a useful marker of  
153 humoral immune activation in each HCW. Some studies of nAb responses in severe,  
154 mild and asymptomatic disease have highlighted rapid waning of nAb within weeks<sup>14-</sup>  
155 <sup>16, 24</sup>, with others finding a more sustained neutralising response<sup>25-27</sup>. We analysed  
156 the nAb response in HCW at 16-18 weeks after UK lockdown and found that 90%  
157 could neutralise pseudotype virus. There was a range of nAb titres detectable, with  
158 66% having an IC50 titre of >200 (Fig. 2b-c), a correlate of protection in SARS-CoV-  
159 2 based on viral challenge in macaque studies<sup>28</sup>. Ten percent of HCW with  
160 laboratory-confirmed SARS-CoV-2 infection demonstrated no detectable neutralising  
161 response (Fig. 2b-c). Typical nAb profiles in the high (IC50  $\geq 200$ ), low (IC50 50-199)  
162 and none (IC50  $\leq 49$ ) categories are shown (Extended Data, Fig 4a). The nAb  
163 response positively correlated with peak S1 IgG and peak NP IgG/IgM (Fig. 2d).  
164 Peak S1 IgG tended to be lower in those reporting non-case defining symptoms and  
165 those who were asymptomatic compared to those with case-definition symptoms  
166 (Fig. 2e). However, the nAb IC50 titre at 16-18 weeks after lockdown was maintained  
167 at a similar level across these three symptom groups (Fig. 2f). Eighty-eight percent

168 of HCW aged  $\geq 50$ y developed nAb at an IC<sub>50</sub> of  $>200$  compared with 59% of  
169 younger HCW aged 24-49y;  $p=0.041$  (Fig. 2g). Peak S1 IgG Ab and nAb IC<sub>50</sub>  
170 increased with age in females (Fig 2h). We looked in more detail at comparative  
171 features of infected individuals in the HCW cohort who did or did not show a nAb  
172 response at 16-18 weeks (Extended Data, Fig. 4b-d); we cannot discount the  
173 possibility that these individuals may have shown an earlier response that had  
174 waned by 16-18 weeks. These 7 HCW with no nAbs spanned an age-range of 26-  
175 53y and tended to be at the lower end of the HCW age-range. Although this sub-  
176 study was not powered to investigate stratified demographic differences, we looked  
177 at features such as gender, ethnicity, clinical role or location, use of personal  
178 protective equipment (PPE) or symptom profile and found no difference between  
179 those that made nAb and those that did not, though there was a trend to more male  
180 non-neutralisers.

181

### 182 **T cell and nAb responses are sometimes discordant**

183 To better understand complementarity between nAb and T cells, we next compared  
184 the T cell, S1 IgG and nAb responses in individual HCW. T cell responses to Spike  
185 and NP protein correlated with peak S1 IgG titre, but with weak correlation  
186 coefficients partly attributable to lack of T cell responses in some HCW with positive  
187 antibody titres to Spike and NP (Fig. 3a; blue box in Extended Data Figs. 5a, d).  
188 Correlations between peak NP IgG/IgM titre and T cell responses to Spike and NP  
189 protein showed similar results (Extended Data Fig. 6a). Just over half HCW were  
190 discordant for T cell and S1 IgG responses, making no T cell response to Spike  
191 protein and 15% made no T cell response to NP (Extended Data Fig. 5a-f). While we  
192 found no differences in terms of age, gender, ethnicity, symptom profile, clinical role  
193 or PPE use, there tended to be more non-responders among Black, Asian and  
194 minority ethnic (BAME) HCW.

195

196 In Fig. 2b, we showed that 10% of infected HCW lacked detectable nAb at 16-18  
197 weeks after UK lockdown. To understand the complementarity between T cell and  
198 nAb responses in individual HCW, we analysed responses of all HCW ranked either  
199 by nAb IC<sub>50</sub> titre or cumulative T cell response. We first arrayed HCW responses  
200 ranked by magnitude of nAb response (Fig. 3b). Neutralisation IC<sub>50</sub> values for all  
201 HCW were plotted in relation to our indicative, protective cut-off value of  $>200$  (dotted

202 horizontal red line in lower panel). HCW lacking detectable nAb are indicated by 7  
203 black arrows on the left. Their cumulative T cell response frequencies against viral  
204 antigens are shown in the panel above and are relatively low. Relating lack of nAbs  
205 to T cell responses to different specific antigens we show that none of the 7 HCW  
206 without detectable nAb make a T cell response to Spike protein (Extended data Fig  
207 6b). The addition of data from Spike MEP pools (potentially encompassing CD8  
208 responses as well) revealed low T cell responses to Spike in 4/7 HCW lacking a nAb  
209 response (Extended data Fig 6c). Exploring T cell responses to NP protein and NP,  
210 M, and ORF3a/7a MEP pools showed 5/7 HCW without detectable nAb making a T  
211 cell response (Extended data Fig 6d). Furthermore, there were OLP T cell responses  
212 in 5/7 HCW lacking nAb (Extended data Fig 6e). Thus HCW lacking nAb tend to lack  
213 responses to Spike while maintaining low frequency T cells to other specificities.

214

215 Examining the converse, we then arrayed HCW responses ranked by magnitude of  
216 cumulative T cell response (Fig 3c). From this plot, HCW with the lowest cumulative  
217 T cell response (to the left of the plot) have a range of nAb responses from none to  
218 >200 IC50. One young, asymptomatic, female HCW with a good peak S1 IgG titre  
219 had no T cell response to any antigens tested but made nAbs with a titre of 143,  
220 which may be insufficient for functional protection (Fig 3b,c indicated by +). Another  
221 female HCW with a good S1 IgG titre, also had no T cell response to any antigens  
222 tested, but made nAbs with a titre of 747 (Fig 3b,c indicated by \*). Assessing T cell  
223 responses ranked simply on the basis of presence or absence of recognition of  
224 proteins and pools (rather than magnitude of response) indicates that those lacking a  
225 nAb response (black arrows) showed T cell responses against 2 to 5 antigens  
226 (Extended data Fig 6f). Taken together, the data show discordance of nAb and T cell  
227 responses in individual HCW.

228

229 Of the 76 HCW studied with mild or asymptomatic laboratory-confirmed SARS-CoV-  
230 2 infection, 64% had one or more case-defining symptoms, 25% had non-case-  
231 defining symptoms and 11% were asymptomatic. Looking at T cell immunity and nAb  
232 levels across these symptom-stratified groups at 16-18 weeks, T cell responses  
233 tended to be higher in infected HCW with case defined symptoms. Responses to M  
234 MEP and ORF3a OLP were significantly higher in HCW reporting case definition  
235 symptoms than those that were asymptomatic (Extended Data Fig. 7a, b).

236 Importantly, there was no significant fall in nAb titres across case-defining, non-case-  
237 defining symptoms and asymptomatic HCW groups (Fig. 2d) with 65%, 68% and  
238 63% respectively showing an IC50 >200. Thus, the majority of HCW with laboratory-  
239 confirmed infection have a detectable (and likely protective) level of nAbs at 16-18  
240 weeks, whilst the 10% who lack detectable nAb have fewer T cells directed against  
241 Spike but can show reactivity to other regions of the viral proteome.

242

## 243 Discussion

244 Much debate has focused on the possibility that the Ab response to SARS-CoV-2  
245 may be short-lived, while T cell recognition may be strong, durable, and more  
246 common<sup>14,16,17,23,27,29</sup>. Mild or asymptomatic infection are very common but are not  
247 usually diagnosed contemporaneously, making assessment of the durability of  
248 immunity in this common group challenging. Here we describe a cross-sectional  
249 study of an exposed HCW cohort at 16-18 weeks after UK lockdown who had mild or  
250 asymptomatic infection picked up by repeated PCR and serological testing. This  
251 cohort shows variable T cell responses across the viral proteome sampled, with only  
252 two HCW with lab-confirmed COVID-19 showing no detectable T cell response  
253 across all the platforms tested. In this study, 90% of HCW with asymptomatic or mild  
254 COVID-19 had nAb at 16-18 weeks after UK lockdown and 66% had titres >200. In  
255 light of some reports of rapid waning of nAbs this result was surprising<sup>15-17, 24,29</sup>. Here  
256 we show a complex pattern of T cell and nAb responses for individual HCW.  
257 Analysis of nAbs shows that the majority of laboratory confirmed SARS-CoV-2  
258 infected HCW with no symptoms or only mild disease had relatively high nAb IC50 at  
259 16-18 weeks after UK lockdown. These IC50s were in the same range as those  
260 defined as conferring functional protection in macaque challenge studies<sup>28</sup>. In terms  
261 of neutralisation observations in humans, a study of SARS-CoV-2 susceptibility  
262 during an outbreak on a fishing vessel indicated a lack of infection in those showing  
263 a prior nAb titre (IC50) >1/160<sup>30</sup>. In infection by SARS-CoV-1, nAbs are often lost by  
264 1-2 years after infection<sup>19,31</sup>, whereas T cell responses can persist for up to 17y after  
265 SARS-CoV-1<sup>3</sup>. Longitudinal follow-up of nAb versus T cell kinetics in the  
266 COVIDsortium cohort will illuminate T cell and nAb trajectories over time.

267

268 In terms of severe COVID-19 risk, two of the strongest factors identified have been  
269 gender and age<sup>32</sup>. We found a positive correlation between both S1 IgG Ab level and



270 nAb IC50 with age in female study participants. Other observations have suggested  
271 a higher T cell response to mitogens in females with acute hospitalised COVID-19<sup>33</sup> ;  
272 we observed higher memory T cell responses to Spike antigen in older males at 16-  
273 18 weeks after UK lockdown. Thus, in this asymptomatic/mild cohort of HCW, the  
274 nAb response increases significantly with age in females, while it is the T cell  
275 response that increases significantly with age in males.

276  
277 A cautionary note about the ephemeral nature of adaptive immunity to coronaviruses  
278 comes from data for annual reinfections with the four seasonal coronaviruses and  
279 emerging data for reinfection by SARS-CoV-2<sup>34,35</sup>. Some studies have raised  
280 concern about the durability of serum antibodies and B cell memory, with data  
281 pointing towards impaired germinal centre reactions in severe acute COVID-19<sup>29</sup>.  
282 Other studies have focused on the potential for rapid waning of nAb after mild SARS-  
283 CoV-2 infection<sup>14,15</sup>. However we find nAb detectable in the majority of HCW  
284 sampled 16-18 weeks after mild/asymptomatic infection. Some T cell data indicates  
285 that even asymptomatic people and household contacts develop low-frequency T  
286 cell responses, in line with results from the HCW without laboratory confirmed  
287 infection using one of our platforms with higher T cell numbers<sup>6</sup>. We show here that  
288 infected HCW can display highly heterogeneous T cell recognition of epitopes from  
289 diverse SARS-CoV-2 structural and non-structural proteins, but it is not yet possible  
290 to decode the differential impacts of these responses for protection. Analysis of T cell  
291 response repertoire in convalescent, hospitalised COVID-19 patients argues that  
292 breadth of T cell response is a marker of mild disease<sup>36</sup>.

293  
294 In summary, this study of HCW with laboratory confirmed SARS-CoV-2 infection  
295 finds that in the majority of these working adults there is immunity at 16-18 weeks  
296 comprising nAb (often at a level likely to protect), usually complemented by multi-  
297 specific T cell responses. Understanding protective immunity in the population will  
298 require simultaneous scrutiny of T cell and antibody responses.

299  
300  
301  
302  
303

## 304 References

305

- 306 1. Ni, L et al., Detection of SARS-CoV-2 specific humoral and cellular immunity  
307 in COVID-19 convalescent individuals. *Immunity* **52**, 971-977 (2020)
- 308 2. Griffoni, A. et al., Targets of T Cell Responses to SARS-CoV-2 Coronavirus  
309 in Humans with COVID-19 Disease and Unexposed Individuals. *Cell* **181**,  
310 1489-1501. (2020).
- 311 3. Le Bert N et al., SARS-CoV-2-specific T cell immunity in cases of COVID-19  
312 and SARS, and uninfected controls. *Nature* **584**, 457-462 (2020)
- 313 4. Peng, Y. et al., Broad and strong memory CD4<sup>+</sup> and CD8<sup>+</sup> T cells induced  
314 by SARS-CoV-2 in UK convalescent individuals following COVID-19. *Nat.*  
315 *Immunol.* <https://www.nature.com/articles/s41590-020-0782-6>
- 316 5. Thieme, CJ et al., Robust T cell response towards spike, membrane, and  
317 nucleocapsid SARS-CoV-2 proteins is not associated with recovery in critical  
318 COVID-19 patients. *Cell Rep Med* ;100092. doi: 10.1016/j.xcrm.2020.100092
- 319 6. Sekine T. et al., Robust T cell immunity in convalescent individuals with  
320 asymptomatic or mild COVID-19. *Cell*  
321 <https://doi.org/10.1016/j.cell.2020.08.017> (2020)
- 322 7. Altmann DM and Boyton RJ. SARS-CoV-2 T cell immunity: Specificity,  
323 function, durability, and role in protection. *Sci Immunol.* Vol. **5**, Issue 49,  
324 eabd6160 (2020).
- 325 8. Kreer C, et al., . Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-  
326 Neutralizing Antibodies from COVID-19 Patients. *Cell* **182**(4):843-854.e12.
- 327 9. Treibel TA et al., COVID-19: PCR screening of asymptomatic health-care  
328 workers at London hospital. *The Lancet* **395**, 1608-1610 (2020)
- 329 10. Augusto JB et al., Healthcare Workers Bioresource: Study outline and  
330 baseline characteristics of a prospective healthcare worker cohort to study  
331 immune protection and pathogenesis in COVID-19.  
332 <https://wellcomeopenresearch.org/articles/5-179> (2020)
- 333 11. Iversen, K et al. Risk of COVID-19 in health-care workers in Denmark: an  
334 observational cohort study. *Lancet Inf Dis.*  
335 [https://www.thelancet.com/article/S1473-3099\(20\)30589-2/fulltext](https://www.thelancet.com/article/S1473-3099(20)30589-2/fulltext) (2020).
- 336 12. Kluytmans-van-den-Burgh, MFQ et al., Prevalence and clinical presentation  
337 of health care workers with symptoms of coronavirus disease 2019 in 2 Dutch

- 338 hospitals during an early phase of the pandemic. *JAMA Netw Open* **3(5)**  
339 e209673
- 340 13. Houlihan CF et al., Pandemic peak SAR-CoV-2 infection and seroconversion  
341 rates in London frontline health-care workers. *The Lancet* **396**, e6-7 (2020)
- 342 14. Seow J et al., Longitudinal evaluation and decline of antibody responses in  
343 SARS-CoV-2 infection.  
344 <https://www.medrxiv.org/content/10.1101/2020.07.09.20148429v1> (2020)
- 345 15. Long Q-X. et al., Clinical and immunological assessment of asymptomatic  
346 SARS-CoV-2 infections. *Nat Med.* **26**, 1200–1204(2020)
- 347 16. Chen, Y. et al., A comprehensive, longitudinal analysis of humoral responses  
348 specific to four recombinant antigens of SARS-CoV-2 in severe and non-  
349 severe COVID-19 patients. <https://doi.org/10.1371/journal.ppat.1008796>  
350 (2020)
- 351 17. Canete PF and Vinuesa CG. COVID-19 makes B cells forget, but T cells  
352 remember. *Cell* <https://doi.org/10.1016/j.cell.2020.09.013>
- 353 18. Kucharski AJ and Nilles, EJ. Using serological data to understand  
354 unobserved SARS-CoV-2 risk in health-care settings. *Lancet Inf Dis* S1473-  
355 3099(20)30579-X (2020)
- 356 19. Li CK, et al., T cell responses to whole SARS coronavirus in humans. *J*  
357 *Immunol.* **15;181(8):5490-500.** (2008)
- 358 20. Mateus J, et al., Selective and cross-reactive SARS-CoV-2 T cell epitopes in  
359 unexposed humans. *Science.* **4:** eabd3871 doi: 10.1126/science.abd3871.  
360 (2020)
- 361 21. Bacher, P. et al., Pre-existing T cell memory as a risk factor for severe  
362 COVID-19 in the elderly.  
363 <https://www.medrxiv.org/content/10.1101/2020.09.15.20188896v1.full.pdf>  
364 (2020)
- 365 22. Sette A, Crotty S. Pre-existing immunity to SARS-CoV-2: the knowns and  
366 unknowns. *Nat Rev Immunol.* **20(8):457-458** (2020)
- 367 23. Sattler A, et al., SARS-CoV-2 specific T-cell responses and correlations with  
368 COVID-19 patient predisposition. *J Clin Invest.* **24:**140965. doi:  
369 10.1172/JCI140965 (2020)
- 370 24. Wang K, et al., Longitudinal dynamics of the neutralizing antibody response  
371 to SARS-CoV-2 infection. *Clin Infect Dis.* Aug 3:ciaa1143. (2020)

- 372 25. Rodda, MB et al., Functional SARS-CoV-2-specific immune memory persists  
373 after mild COVID-19.  
374 <https://www.medrxiv.org/content/10.1101/2020.08.11.20171843v2>
- 375 26. Wajnberg, A. et al., SARS-CoV-2 infection induces robust, neutralizing antibody  
376 responses that are stable for at least three months.  
377 <https://www.medrxiv.org/content/10.1101/2020.07.14.20151126v1> (2020)
- 378 27. Wu J. et al., SARS-CoV-2 infection induces sustained humoral immune  
379 responses in convalescent patients following symptomatic COVID-19.  
380 <https://www.medrxiv.org/content/10.1101/2020.07.21.20159178v1> (2020)
- 381 28. Yu J, et al., DNA vaccine protection against SARS-CoV-2 in rhesus  
382 macaques. *Science*. Aug 14; **369**(6505):806-811 (2020)
- 383 29. Kaneko, N et al., Loss of Bcl-6-expressing T follicular helper cells and  
384 germinal centers in COVID-19. *Cell* **183**, 1-15. (2020)
- 385 30. Addetia, A. et al., Neutralizing antibodies correlate with protection from  
386 SARS-CoV-2 in humans during a fishery vessel outbreak with high attack  
387 rate. <https://www.medrxiv.org/content/10.1101/2020.08.13.20173161v1>  
388 (2020)
- 389 31. Temperton NJ et al., Longitudinally profiling neutralizing antibody response to  
390 SARS coronavirus with pseudotypes. *Emerg Infect Dis*. **11**(3):411-6 (2005)
- 391 32. Docherty, AB et al., Features of 20 133 UK patients in hospital with covid-19  
392 using the ISARIC WHO Clinical Characterisation Protocol: prospective  
393 observational cohort study. *BMJ* **369**:m1985 (2020).
- 394 33. Takahashi, T et al., Sex differences in immune responses to SARS-CoV-2 that  
395 underlie disease outcomes. *Nature* <https://doi.org/10.1038/s41586-020-2700-3>  
396 (2020)
- 397 34. To, KW. et al., COVID-19 re-infection by a phylogenetically distinct SARS-  
398 coronavirus-2 strain confirmed by whole genome sequencing. *Clin Inf Dis*.  
399 *ciaa1275*, <https://doi.org/10.1093/cid/ciaa1275> (2020)
- 400 35. Edridge AWD et al., Seasonal coronavirus protective immunity is short-  
401 lasting. *Nat Med*. s41591-020-1083-1 (2020).
- 402 36. Nelde A et al., SARS-CoV-2 derived peptides define heterologous and  
403 COVID-19-induced T cell recognition. *Nat Immunol* ep 30. doi:  
404 [10.1038/s41590-020-00808-x](https://doi.org/10.1038/s41590-020-00808-x). Online ahead of print (2020)  
405

406 **Methods**

407

408 **Ethics statement**

409 The COVIDsortium Healthcare Workers bioresource was approved by the ethical  
410 committee of UK National Research Ethics Service (20/SC/0149) and registered on  
411 ClinicalTrials.gov (NCT04318314). The study conformed to the principles of the  
412 Helsinki Declaration, and all subjects gave written informed consent.

413

414 Pre-pandemic healthy donor samples were collected and cryopreserved before  
415 October 2019. Pre-pandemic cohort 1 and 2 samples were recruited under ethics  
416 numbers 17/LO/0800 and 11/LO/0421 respectively.

417

418 **COVIDsortium Healthcare Worker Participants**

419 Adult HCW (>18 years old) from a range of clinical settings who self-declared as fit  
420 to attend work were invited to participate via local advertisement of the project (see  
421 <https://covid-consortium.com>). Full study details of the bioresource (participant  
422 screening, study design, sample collection, and sample processing) have been  
423 previously published<sup>10</sup>.

424

425 A cohort of 400 HCW was initially recruited from St Bartholomew's Hospital, London,  
426 in the week of UK lockdown (23<sup>rd</sup>-31<sup>st</sup> March 2020). All participants were  
427 asymptomatic and self-declared fit to attend work in hospital. Recruitment was  
428 extended (27<sup>th</sup> April-7<sup>th</sup> May 2020) to include 331 additional participants from multiple  
429 sites: St Bartholomew's Hospital (n=101 additional), NHS Nightingale Hospital  
430 (n=10), and Royal Free NHS Hospital Trust (n=220).

431

432 A prospective, observational, longitudinal cohort design was used and consisted of  
433 questionnaires exploring demographic, clinical and exposure risks, and sample  
434 collection at baseline and weekly follow-up for 15w from the start of each cohort.  
435 Participants were asked to provide details and timing of symptoms in the 3 months  
436 prior to baseline, and for those who were unable to attend follow-up visits (due to  
437 shift rostering, annual leave or self-isolation), the reason for non-attendance was  
438 collected, to ensure capture of information regarding isolation due to participant  
439 symptoms or household contacts. On return from self-isolation with symptoms,

440 convalescent samples were collected. Further follow-ups at 6 and 12 months are  
441 planned.

442

443 Complete details of the sampling protocol have been previously published<sup>10</sup>. Initial  
444 analysis of samples for determining infection with SARS-CoV-2 included: nasal RNA  
445 stabilizing swabs baseline and weekly with reverse transcriptase polymerase chain  
446 reaction (RT-PCR): Roche cobas® SARS-CoV-2 test; Ab testing baseline and  
447 weekly: IgG Ab assay to spike protein S1 antigen, (EUROIMMUN Anti-SARS-CoV-2  
448 enzyme-linked immunosorbent assay [ELISA]); and anti-nucleocapsid total antibody  
449 assay (ROCHE Elecsys Anti-SARS-CoV-2 electrochemiluminescence immunoassay  
450 [ECLIA]). Antibody ratios  $\geq 1.1$  were considered test positive for the EUROIMMUN  
451 SARS-CoV-2 ELISA and  $>1$  was considered test positive for the ROCHE Elecsys  
452 anti-SARS-CoV-2 ECLIA following published Public Health England (PHE)  
453 evaluations.

454

455 Evaluation of Roche Elecsys Anti-SARS-CoV-2 serology assay for the detection of  
456 anti-SARS-CoV-2 antibodies. PHE, UK 110620.

457 [[https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attach  
458 ment\\_data/file/891598/Evaluation\\_of\\_Roche\\_Elecsys\\_anti\\_SARS\\_CoV\\_2\\_PHE\\_200  
459 610\\_v8.1\\_FINAL.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/891598/Evaluation_of_Roche_Elecsys_anti_SARS_CoV_2_PHE_200610_v8.1_FINAL.pdf)]

460

461 Evaluation of Euroimmun Anti-SARS-CoV-2 ELISA (IgG) serology assay for the  
462 detection of antibodies. PHE, UK

463 [[https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attach  
464 ment\\_data/file/893433/Evaluation\\_of\\_Euroimmun\\_SARS\\_CoV\\_2\\_ELISA\\_IgG\\_\\_1\\_.p  
465 df](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/893433/Evaluation_of_Euroimmun_SARS_CoV_2_ELISA_IgG__1_.pdf)]

466

467 At baseline, information relating to demographics and exposures was collected via a  
468 standardised questionnaire. Mean age of the cohort (n=731) was  $38\pm 11$  years; 33%  
469 are male, 31% nurses, 20% doctors, and 19% work in intensive care units. COVID-  
470 19-associated risk factors were: 37% Black, Asian or minority ethnicities (BAME);  
471 18% smokers; 13% obesity; 11% asthma; 7% hypertension and 2% diabetes  
472 mellitus<sup>10</sup>. At weekly follow-up visits information relating to symptom burden was  
473 recorded using a standardised questionnaire. Symptoms were classified as follows:

474 'case-defining' (fever, new continuous dry cough or a new loss of taste or smell),  
475 'non-case-defining' (specific symptoms other than case-defining symptoms, or  
476 unspecified symptoms), or asymptomatic (no symptoms reported).

477

478 Case definition for coronavirus disease 2019 (COVID-19), as of 29 May 2020

479 European Centre for Disease Prevention and Control

480 [<https://www.ecdc.europa.eu/en/covid-19/surveillance/case-definition>]

481

482 A total of 731 HCW underwent 16 weeks of serial assessment (attending unless ill,  
483 self-isolating, on holiday, or redeployed). Across the main study cohort, 48  
484 participants had positive RT-PCR results with 157 (21.5%) seropositive participants.  
485 Infections were asymptomatic or mild with only two hospital admissions (neither  
486 requiring intensive care admission, both discharged well). The cohort therefore  
487 represents working age community COVID-19 rather than hospitalised COVID-19.

488

489 The cross-sectional case controlled sub-study (n=136) collected samples at 16-18  
490 weeks after UK lockdown (Extended Data Table 1a, Extended Data Fig. 8). The  
491 cross-sectional case controlled sub-study included 76 HCW (mean age 41y, 36%  
492 male) with laboratory defined evidence of SARS-CoV-2 either by SARS-CoV-2  
493 positive PCR and/or positive for spike IgG (Euroimmun ELISA)/ NP IgG/IgM antibody  
494 (Roche Elecsys). Fifty-seven percent reported one or more case defining COVID-19  
495 symptoms. Twenty-four percent reported non-case defining symptoms and 19%  
496 were asymptomatic at baseline, during 16-week follow-up or in the 3 months prior to  
497 baseline. A second age, gender, and ethnicity matched subgroup of sixty HCW were  
498 recruited (mean age 39y, 37% male) who were SARS-CoV-2 PCR negative and  
499 negative for Spike IgG (Euroimmun ELISA) and NP IgG/IgM antibody (Roche  
500 Elecsys) tests throughout the 16-week follow-up. However, forty-four percent  
501 reported one or more case defining COVID-19 symptoms, 41% non-case defining  
502 symptoms and 15% were asymptomatic at baseline, during 16-week follow-up and in  
503 the 3 months prior to baseline.

504

505

506

## 507 **Isolation of PBMC**

508 Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood  
509 samples using Pancoll (Pan Biotech) or Histopaque®-1077 Hybri-Max™ (Sigma-  
510 Aldrich) density gradient centrifugation in SepMate™ tubes (Stemcell) according to  
511 the manufacturer specifications. Isolated PBMCs were cryopreserved in fetal calf  
512 serum containing 10% DMSO and stored in liquid nitrogen.

## 513 **Isolation of serum**

514 Whole blood samples were collected in SST vacutainers (VACUETTE® #455092)  
515 with inert polymer gel for serum separation and clot activator coating. After  
516 centrifugation at 1000 X g for 10 minutes at room temperature, serum layer was  
517 aliquoted and stored at -80°C for specific SARS-CoV-2 Ab titre detection by ELISA  
518 and for SARS-CoV-2 Spike pseudotyped virus neutralisation assays.

## 519 **SARS-CoV-2 specific Ab titre**

520 Anti-SARS-CoV-2 S1 IgG ELISA (EUROIMMUN) was performed on a Stratec  
521 Biomedical Gemini automated ELISA platform as described. The optical density was  
522 detected at 450nm, and a ratio of the reading of each sample to the reading of the  
523 calibrator included in the kit was calculated for each sample. An OD ratio of  $\geq 1.1$  was  
524 interpreted as positive for S1 antibodies by manufacturer's recommendation.

525 Elecsys® Anti-SARS-CoV-2 nucleocapsid total Ab ELISA (ROCHE) was performed  
526 as described. Results are reported as numeric values in the form of a cut-off index  
527 (COI; signal sample/cut-off) as well as in the form of qualitative results non-reactive  
528 (COI < 1.0; negative) and reactive (COI  $\geq 1.0$ ; positive).

## 529 **Recombinant proteins**

530 The SARS-CoV-2 S1 Spike antigen and Nucleoprotein was obtained from the Centre  
531 for AIDS Reagents (CFAR), National Institute for Biological Standards and Control  
532 (NIBSC), UK: SARS-CoV-2 Nucleoprotein and S1 Spike antigen from Dr Peter  
533 Cherepanov, Francis Crick Institute, UK.



## 534 **Mapped epitope pools (MEP)**

535 Pools of 13-20mer peptides based on the protein sequences of SARS-CoV-2 S1  
536 (Spike), nucleoprotein (NP), membrane (M) and open reading frames 3a and 7a  
537 (ORF3a/7a) described previously were synthesized<sup>4</sup> (GL Biochem Shanghai Ltd,  
538 China). To stimulate PBMC, separate pools of sequences for Spike (18 peptides),  
539 NP (10 peptides), M (6 peptides) and ORF3a/7a (7 peptides) were used, see  
540 Extended Data Table 2a). A second mapped epitope pool of SARS-CoV-2 S1  
541 peptides (Spike MEP2) based on alignment of all sequences of published SARS-  
542 CoV-1 epitopes ([www.iedb.org](http://www.iedb.org); search criteria: positive assays only, T cells assays,  
543 host: human) with the Spike-SARS-CoV-2 sequence and 15-mer peptides  
544 synthesised to cover the homologous sequences. In addition, we synthesised 15-  
545 mer peptides covering the predicted SARS-CoV-2 Spike epitopes<sup>3</sup> to give a total of  
546 55 peptides in this pool (Spike MEP2), see Extended Data Table 2b

## 547 **Overlapping peptide pools (OLP):**

548 15-mer peptides overlapping by 10 amino acids spanning the entire protein  
549 sequence of SARS-CoV-2 nucleoprotein (NP), Membrane (M) and ORF3a were  
550 synthesized (GL Biochem Shanghai Ltd; see Extended Data Tables 2b). To  
551 stimulate PBMC, the peptides were divided into 4 pools covering NP (NP-1, NP-2 ,  
552 41 peptides each), M (43 peptides), and ORF3a (53 peptides).

## 553 **IFN $\gamma$ -ELISpot Assay**

554 Unless otherwise stated, culture medium for human T cells was sterile 0.22 $\mu$ M  
555 filtered RPMI medium (GibcoBRL) supplemented with 10% by volume heat  
556 inactivated (1h, 64°C) fetal calf serum (FCS; Hyclone, and 1% by volume 100x  
557 penicillin and streptomycin solution (GibcoBRL).

558 For experiments involving T cell stimulation with proteins or MEP peptide pools, pre-  
559 coated ELISpot plates (Mabtech 3420-2APT) were washed x4 with sterile PBS and  
560 were blocked with R10 for 1h at room temperature. 200,000 PBMC were seeded in  
561 R10/well and were stimulated for 18-22h at 37°C with 5%CO<sub>2</sub> with SARS-CoV-2  
562 recombinant proteins (10 $\mu$ g/ml) or MEP pools (10 $\mu$ g/ml/peptide). Internal plate

563 controls were R10 alone (without cells) and anti-CD3 (Mabtech mAb CD3-2). At the  
564 end of the stimulation period, cell culture supernatants were collected and stored for  
565 later cytokine analysis by Luminex. ELISpot plates were developed with human  
566 biotinylated IFN $\gamma$  detection Ab, directly conjugated to alkaline phosphatase (7-B6-1-  
567 ALP, Mabtech; 1 $\mu$ g/ml), diluted in PBS with 0.5% FCS, incubating 50 $\mu$ l/well for 2h at  
568 room temperature. This was followed by 50 $\mu$ l/well of sterile filtered BCIP/NBT-plus  
569 Phosphatase Substrate (Mabtech) for 5 minutes at room temperature. Plates were  
570 washed in ddH<sub>2</sub>O and left to dry completely before being read on AID-ELISpot plate  
571 reader. For experiments involving T cell stimulation with OLP peptide pools and  
572 Spike MEP2 pool ELISpot plates (AID classic ELISpot plate reader (Autoimmun  
573 Diagnostika GMBH, Germany) were coated with human anti-IFN $\gamma$  Ab (1-D1K,  
574 Mabtech; 10 $\mu$ g/ml) in PBS overnight at 4°C. Plates were washed x6 with sterile PBS  
575 and were blocked with R10 for 2h at 37°C with 5% CO<sub>2</sub>. PBMC were thawed and  
576 rested in R10 for 3h at 37 °C with 5%CO<sub>2</sub> before being counted. 400,000 PBMC  
577 were seeded in R10/well and were stimulated for 16-20h with SARS-CoV-2 OLP  
578 pools or Spike MEP2 pool (2 $\mu$ g/ml/peptide). Internal plate controls were R10 alone  
579 (without cells) and two DMSO wells (negative controls), concanavalin A (ConA,  
580 positive control; Sigma-Aldrich) and FEC (HLAI-restricted peptides from influenza,  
581 Epstein-Barr virus, and CMV; 1 $\mu$ g/ml). ELISpot plates were developed with human  
582 biotinylated IFN- $\gamma$  detection antibody (7-B6-1, Mabtech; 1 $\mu$ g/ml) for 3h at room  
583 temperature, followed by incubation with goat anti-biotin alkaline phosphatase  
584 (Vector Laboratories; 1:1000) for 2h at room temperature, both diluted in PBS with  
585 0.5% BSA by volume (Sigma-Aldrich), and finally with 50 $\mu$ l/well of sterile filtered  
586 BCIP/NBT Phosphatase Substrate (ThermoFisher) for 7 minutes at room  
587 temperature. Plates were washed in ddH<sub>2</sub>O and left to dry overnight before being  
588 read on an AID classic ELISpot plate reader (Autoimmun Diagnostika GMBH,  
589 Germany).

590 Analysis of ELISpot data was performed in Microsoft Excel. The average of two R10  
591 alone wells or DMSO (Sigma-Aldrich) wells was subtracted from all peptide  
592 stimulated wells and any response that was lower in magnitude than 2 standard  
593 deviations of the sample specific control wells was not considered a peptide specific  
594 response. Results were expressed as difference in (delta) spot forming cells per 10<sup>6</sup>  
595 PBMC between the negative control and protein/peptide stimulation conditions. We

596 excluded the results if negative control wells had  $>100$  SFU/ $10^6$  PBMC or positive  
597 control wells (ConA or anti-CD3) were negative. Results were plotted using Prism v.  
598 7.0e and 8.0 for Mac OS (GraphPad).

### 599 **Cytokine measurement**

600 Concentrations of IL-4, IL-5, IL-13, IL-17a and IL-23 were measured by multiplex  
601 Luminex® assay (Bio-Techne) on a Bio-Plex 200 instrument (Bio-Rad Laboratories,  
602 Ltd). Cytokine levels in cell culture supernatants in response to PBMC stimulation  
603 with Spike or NP protein were calculated in Microsoft Excel by subtracting values  
604 obtained for media only controls. Standard curves were plotted using Prism 8.0 for  
605 Mac OS (GraphPad).

### 606 **Cell Lines**

607 HEK-293T and Huh7 (both ATCC) were cultured and maintained in high glucose  
608 Dulbecco's Modified Eagle's Medium and supplemented with GlutaMAX, 10% (v/v)  
609 heat-inactivated foetal bovine serum (FBS, 56°C for 30 minutes), 100IU/ml penicillin  
610 and 100µg/ml streptomycin. Cell lines were cultured at 37°C with 5% CO<sub>2</sub>.

### 611 **Production and titration of SARS-CoV-2 pseudotyped lentiviral reporter** 612 **particles**

613 Pseudotype stocks were prepared by linear polyethylenimine 25K (Polysciences) co-  
614 transfection of HEK-293T (ATCC) with SARS-CoV-2 spike pcDNA expression  
615 plasmid, HIV gag-pol p8.91 plasmid and firefly luciferase expressing plasmid  
616 pCSFLW at a 1:1:1.5 ratio<sup>37,38</sup>.  $2.5 \times 10^4$  cells/cm<sup>2</sup> were plated 24h prior to transfection  
617 in 60cm<sup>2</sup> cell culture dishes. 48 and 72h post transfection, pseudotype-containing  
618 culture medium was harvested and centrifuged at 500xg for 5 minutes to clear cell  
619 debris. Aliquots were stored at -80°C. TCID assays were performed by transduction  
620 of Huh7 cells to calculate the viral titre and infectious dose for neutralisation assays.  
621 p24 ELISA was also used to determine input concentration.

622

623

## 624 **p24 ELISA**

625 Pseudotype stock concentrations were determined by ELISA for p24 protein  
626 concentration as previously described<sup>39</sup>. White ELISA plates were pre-coated with  
627 5µg/ml sheep anti-HIV-1 p24 antibody (Aalto Bio Reagents) at 4°C overnight.  
628 Pseudoviral supernatants were treated with 1% Empigen BB (Merck) for 30 min at  
629 56°C and then plated at 1:10 dilution in Tris-buffered saline (TBS) on pre-coated  
630 plates and incubated for 3h at room temperature. Alkaline phosphatase-conjugated  
631 mouse anti-HIV-1 p24 monoclonal antibody (Aalto Bio Reagents) in TBS, 20% (v/v)  
632 sheep serum, 0.05% (v/v) Tween 20 was then added and incubated for 1h at room  
633 temperature. After 4 washes with phosphate-buffered saline (PBS)-0.01% (v/v)  
634 Tween 20 and 2 washes with ELISA Light washing buffer (ThermoFisher), CSPD  
635 substrate with Sapphire II enhancer (ThermoFisher) was added and incubated for 30  
636 minutes at room temperature before chemiluminescence detection using a  
637 CLARIOStar Plate Reader (BMG Labtech).

## 638 **Pseudotyped SARS-CoV-2 neutralisation assays**

639 SARS-CoV-2 pseudotype neutralisation assays were conducted using pseudotyped  
640 lentiviral particles as previously described<sup>37-40</sup>. Serum was heat-inactivated at 56°C  
641 for 30 minutes to remove complement activity. Serum dilutions in DMEM were  
642 performed in duplicate in white, flat-bottom 96-well plates (ThermoFisher, #136101)  
643 with a starting dilution of 1 in 20 and 7 consecutive 2-fold dilutions to a final dilution  
644 of 1/2,560 in a total volume of 100µl.  $1 \times 10^5$  RLU of SARS-CoV-2 pseudotyped  
645 lentiviral particles were added to each well and incubated at 37°C for 1h. 8 control  
646 wells per plate received pseudotype and cells only (virus control) and another 8 wells  
647 received cells only (background control).  $4 \times 10^4$  Huh7 cells suspended in 100µl  
648 complete media were added per well and incubated for 72h at 37°C and 5% CO<sub>2</sub>.  
649 Firefly luciferase activity (luminescence) was measured using Steady-Glo®  
650 Luciferase Assay System (Promega) and a CLARIOStar Plate Reader (BMG  
651 Labtech). The curves of relative infection rates (in %) versus the serum dilutions  
652 (log<sub>10</sub> values) against a negative control of pooled sera collected prior to 2016  
653 (Sigma) and a positive neutraliser were plotted using Prism 8 (GraphPad). A non-

654 linear regression method was used to determine the dilution fold that neutralised  
655 50% (IC50).

## 656 **Statistics and reproducibility**

657 Data was assumed to have a non-Gaussian distribution. Non-parametric tests were  
658 used throughout. For single paired and unpaired comparisons Wilcoxon matched-  
659 pairs signed rank test and a Mann-Whitney t-test were used. For multiple paired and  
660 unpaired comparisons Friedman multiple comparisons ANOVA with Dunn's  
661 correction or Kruskal-Wallis one-way Anova with Dunn's correction were used. For  
662 correlations, Spearman's r test was used. A p value <0.05 was considered  
663 significant. Prism v. 7.0e and 8.0 for Mac was used for analysis.

## 664 **Additional references for Methods:**

- 665 37. Ferrara, F. and Temperton, N. (2018). Pseudotype neutralization assays:  
666 From laboratory bench to data analysis. *Methods and Protocols*.  
667 <https://doi.org/10.3390/mps1010008>
- 668 38. Carnell, G. W., Ferrara, F., Grehan, K., Thompson, C. P., & Temperton,  
669 N. J. (2015). Pseudotype-based neutralization assays for influenza: A  
670 systematic analysis. *Frontiers in Immunology*.  
671 <https://doi.org/10.3389/fimmu.2015.00161>
- 672 39. Craig P Thompson, Nicholas Grayson, Robert Paton, et al. Detection of  
673 neutralising antibodies to SARS coronavirus 2 to determine population  
674 exposure in Scottish blood donors between March and May 2020.  
675 medRxiv 2020.04.13.20060467; doi:<https://doi.org/10.1101/2020.04.13.20060467>
- 676
- 677 40. Gibbons, J. M., Marno, K. M., Pike, R., Lee, W. Y. J., Jones, C. E.,  
678 Ogunkolade, B. W., and McKnight, Á. (2020). HIV-1 accessory protein Vpr  
679 interacts with REAF/RPRD2 to mitigate its antiviral activity. *Journal of*  
680 *Virology*. <https://doi.org/10.1101/408161>

681

## 682 **Acknowledgements**

683 The authors wish to thank all the HCW participants for donating their samples and  
684 data for these analyses, and the research teams involved in consenting, recruitment  
685 and sampling of the HCW participants. Funding for COVIDsortium was donated by  
686 individuals, charitable Trusts, and corporations including Goldman Sachs, Citadel  
687 and Citadel Securities, The Guy Foundation, GW Pharmaceuticals, Kusuma Trust,  
688 and Jagclif Charitable Trust, and enabled by Barts Charity with support from UCLH  
689 Charity. Wider support is acknowledged on the COVIDsortium website. Institutional  
690 support from Barts Health NHS Trust and Royal Free NHS Foundation Trust  
691 facilitated study processes, in partnership with University College London and Queen  
692 Mary University London. We thank Antonio Bertoletti for supplying pre-pooled OLPs  
693 and spike MEP2. RJB/DMA are supported by MRC Newton (MR/S019553/1 and  
694 MR/R02622X/1), NIHR Imperial Biomedical Research Centre (BRC):ITMAT, Cystic  
695 Fibrosis Trust SRC, and Horizon 2020 Marie Curie Actions. MKM is supported by the  
696 UKRI/NIHR UK-CIC grant, a Wellcome Trust Investigator Award (214191/Z/18/Z)  
697 and a CRUK Immunology grant (26603). LS is supported by a Medical Research  
698 Foundation fellowship (044-0001). ÁM is supported by Rosetrees trust, The John  
699 Black Charitable Foundation, and Medical College of St Bartholomew's Hospital  
700 Trust. JCM, CM and TAT are directly and indirectly supported by the University  
701 College London Hospitals (UCLH) and Barts NIHR Biomedical Research Centres  
702 and through the British Heart Foundation (BHF) Accelerator Award (AA/18/6/34223).  
703 TAT is funded by a BHF Intermediate Research Fellowship (FS/19/35/34374). MN is  
704 supported by the Wellcome Trust (207511/Z/17/Z) and by NIHR Biomedical  
705 Research Funding to UCL and UCLH.

706 The funders had no role in study design, data collection, data analysis, data  
707 interpretation, or writing of the report.

708

## 709 **Author contributions**


710 R.J.B, D.M.A, M.K.M and Á.M. conceptualised the research project reported. R.J.B.,  
711 D.M.A, and M.K.M supervised the T cell experiments. Á.M. supervised the nAb  
712 experiments. T.B. and A.Se supervised S1 IgG and NP IgG/IgM studies. C.J.R.,  
713 D.B., L.S., N.S., M.D., and O.A. performed and analysed the T cell experiments.  
714 J.M.G. and C.P. performed and analysed the nAb experiments. C.G. and N.T.

715 developed Pseudotyped SARS-CoV-2 neutralisation assays. S.T. performed and J.J.  
716 and A.Se analysed the S1 IgG and NP IgG/IgM assays. T.B., C.M., Á.M., T.T., J.M.,  
717 and M.N. conceptualised and established the HCW cohort. M.J. analysed the HCW  
718 database. R.J.B., T.T., C.M., J.M., M.N., and M.J. designed the 16-18 week sub-  
719 study recruitment. M.J., W.L., M.J., J.R., A.C., G.J., J.L., M.F., A.S., C.M., T.T., and  
720 J.M. collected HCW samples and data, established the HCW cohort data base.  
721 J.M.G., C.P., C.J.R., D.B., S.B., L.S., N.S., M.D., O.A., J.R., and A.C. processed  
722 HCW samples. B.O'B. provided critical reagents. R.J.B., M.J., C.J.R, S.B., L.S.,  
723 J.M.G., and C.P. analysed the data. R.J.B., M.K.M., Á.M., and D.M.A. wrote the  
724 manuscript. C.J.R., L.S., J.M.G., C.P., and M.J. helped prepare the manuscript and  
725 figures. All the authors reviewed and edited the manuscript and figures.

726


### 727 **Competing interests**

728 The authors declare no competing interests.




**Figure 1. T cell responses to SARS-CoV-2 antigens in HCW (laboratory-confirmed COVID-19) at 16-18 weeks after UK lockdown: a-c)** Magnitude of T cell response and proportion of HCW with a summed T cell response within the given ranges (0, 1-19, 20-79,  $\geq 80$   $\Delta$ SFC/ $10^6$  PBMC). **a**, Spike and NP protein (n = 75), **b**) mapped epitope peptide (MEP; n = 75) and **c**) overlapping peptide (OLP) pools (n = 71, ordered by cumulative magnitude) in HCW with laboratory-confirmed SARS-CoV-2 infection (n = 75). **d**) Proportion of HCW with a T cell response to SARS-CoV-2 individual proteins or peptide pools within given ranges (0, 1-19, 20-79,  $\geq 80$   $\Delta$ SFC/ $10^6$  PBMC) in the following groups: HCW cohort with laboratory-confirmed infection (n = 75); HCW cohort with no laboratory-confirmed infection but with one or more case-definition symptoms (n = 26), non-case-definition symptoms (n = 24) or asymptomatic (n = 9); pre-COVID-19 pandemic control cohort 1 (n = 20). **a-b**) Bars at geomean. **a**) Wilcoxon matched-pairs signed rank test. **b**) Friedman multiple comparisons ANOVA with Dunn's correction. Ab, antibody; HCW, health care workers; M, Membrane; ORF, open reading frame; NP, Nucleoprotein; S1, Spike subunit 1; SFC, spot forming cells per  $10^6$  PBMC.






**Figure 2. nAb responses to SARS-CoV-2 antigens in HCW (laboratory-confirmed COVID-19) at 16-18 weeks after UK lockdown:**

**a)** Peak S1 IgG antibody titre and peak NP IgG/IgM Ab titre across the study period in HCW with laboratory-confirmed SARS-CoV-2 infection ( $n = 70$ ). **b)** The distribution of nAb (IC50) titres across the cohort of HCW with laboratory-confirmed infection and **c)** The proportion of HCW with an undetectable (0-49), low (50-199) or high (200+) nAb titre (IC50). **d)** Correlation between peak S1 IgG Ab titre (left) or the peak NP IgG/IgM Ab titre (right) and nAb titre (IC50) in HCW with laboratory-confirmed SARS-CoV-2 infection. **e-f)** Peak S1 IgG Ab titre **e)** and nAb titre (IC50) **f)** in HCW with laboratory-confirmed infection, stratified by symptom group:  $\geq 1$  COVID-19 case-definition symptoms (Red), non-case definition symptoms (Blue) or asymptomatic (Grey) throughout trial and within 3-months of trial initiation. **g)** The proportion of HCW with an undetectable (0-49), low (50-199) or high (200+) nAb titre (IC50) within specified age ranges; 20-29 Y ( $n = 13$ ), 30-39 Y ( $n = 25$ ), 40-49 Y ( $n = 16$ ) and  $\geq 50$  Y ( $n = 16$ ). **h)** Correlations of age vs. peak S1 IgG Ab titre (left) and neutralising antibody titre (IC50; right) in HCW with laboratory-confirmed SARS-CoV-2 infection separated by gender (female, black symbols; male, open symbols). **d, h)** Spearman's rank correlation, least squares log-log lines shown. **a-b, e-f)** bars at geomean. **e, f)** Kruskal Wallis multiple comparison ANOVA with Dunn's correction, not significant. Ab, antibody; nAb, neutralising antibody; S1, Spike subunit 1; SFC, spot forming cells per  $10^6$  PBMC; Y, years.



**Figure 3. Concordant and discordant T cell and nAb responses in HCW (laboratory-confirmed COVID-19) at 16-18 weeks after UK lockdown.** **a**) Correlations between the peak S1 IgG Ab titre and T cell responses to Spike protein (left) or NP protein (right) in HCW with laboratory-confirmed SARS-CoV-2 infection ( $n = 75$ ). **b**) Top panel; Cumulative magnitude of the T cell response to Spike and NP proteins, mapped epitope peptide (MEP and MEP2) panels and overlapping peptide (OLP) panels (top panel) ordered by increasing magnitude of nAb response (bottom panel) or **c**) Magnitude of nAb response (top panel) ordered by increasing cumulative magnitude of T cell response to Spike and NP proteins, MEP/MEP2 panels and OLP panels (bottom panel) in HCW with laboratory-confirmed SARS-CoV-2 infection ( $n = 70$ ). HCW with no nAb (IC50 titre less than 50) are indicated by black arrows. + and \* denote individuals with no T cell response to any protein or peptide pool. **d**) Proportion of HCW with a nAb titre (IC50) or T cell response to Spike and NP proteins within given ranges stratified by symptom group;  $\geq 1$  COVID-19 case definition symptoms ( $n = 43$  or  $48$ ), non-case definition symptoms ( $n = 19$ ) or asymptomatic ( $n = 8$ ) **a**) Spearman's rank correlation. HCW, health care workers; M, Membrane; ORF, open reading frame; nAb, neutralising antibody; NP, Nucleoprotein; S1, Spike subunit 1; SFC, spot forming cells per  $10^6$  PBMC.

Extended Data Fig. 1



**e**

Cytokine	Standard curve	Range (pg/ml)	Laboratory-confirmed SARS-CoV-2 HCW	SARS-CoV-2 PCR negative / S1 IgG Ab negative HCW
IL-4		15 - 3,783	0/71	0/48
IL-5		6 - 1,530	0/71	0/48
IL-13		359 - 87,270	0/71	0/48
IL-17A		12 - 3,150	0/71	0/48
IL-23		143 - 34,780	0/71	0/48

**Extended Data Figure 1. T cell responses to SARS-CoV-2 antigens in HCW with and without laboratory-confirmed SARS-CoV-2 infection 16-18 weeks after UK lockdown:**

**a)** Magnitude of the T cell response to Spike mapped epitope pool 2 (Spike MEP2), overlapping peptide pools (OLP), the summed total response to OLP pools + Spike MEP2, and response to positive control FEC peptide pool (covering CD8 epitopes from flu, EBV, CMV) in HCW with laboratory-confirmed SARS-CoV-2 infection (n = 71).


**b)** Magnitude of the T cell response to Spike MEP2 and OLP pools in the following groups: HCW with laboratory-confirmed SARS-CoV-2 infection (n = 71); HCW with no laboratory-confirmed infection but with  $\geq 1$  COVID-19 case definition symptoms (n = 15), non-case definition symptoms (n = 15) or asymptomatic (n = 10); pre-COVID-19 pandemic control cohort 2 (n = 19).

**c,d)** Magnitude of the T cell response to Spike and NP proteins **c)** and mapped epitope pools (MEP) **d)** in the following groups: HCW with laboratory-confirmed SARS-CoV-2 infection (n = 75); HCW with no laboratory-confirmed infection but with  $\geq 1$  COVID-19 case definition symptoms (n = 26), non-case definition symptoms (n = 24) or asymptomatic (n = 9); pre-COVID-19 pandemic control cohort 1 (n = 20).

**e)** Number of HCW with detectable IL-4, IL-5, IL-13, IL-17A or IL-23 cytokine levels in T cell ELISpot supernatants by Luminex assay. Example cytokine standard curves and the concentration range of each cytokine assay are shown.

**a-d)** Bars at geomean. **a)** Friedman multiple comparisons ANOVA with Dunn's correction. **b-d)** Kruskal-Wallis multiple comparisons ANOVA with Dunn's correction. Ab, antibody; HCW, health care workers; M, Membrane; ORF, open reading frame; NP, Nucleoprotein; S1, Spike subunit 1; SFC, spot forming cells per  $10^6$  PBMC.

Extended data Fig. 2




**Extended Data Figure 2. SARS-CoV-2 specific immune responses in HCW with laboratory-confirmed infection by age:**

**a-d)** Correlations between the peak S1 IgG antibody titre (left) and nAb titre (IC50; right) **a)**, T cell response to individual Spike and NP proteins **b)**, mapped epitope peptide pools (MEP) **c)** or Spike mapped epitope peptide pool 2 (MEP2) and overlapping peptide pools (OLP) **d)** vs. age, coloured by symptom group, in HCW with laboratory-confirmed SARS-CoV-2 infection (n = 71-75): Red,  $\geq 1$  case-definition symptom; Blue,  $\geq 1$  non-case definition symptom; Grey, asymptomatic throughout trial and within 3 months of trial initiation.

**e)** Correlations of age (Y) vs. T cell response to Spike protein (left), Spike MEP (middle), Spike MEP2 (right) in HCW with laboratory-confirmed SARS-CoV-2 infection (Spike protein, Spike MEP, n = 75; Spike MEP2, n = 71) separated by gender (female, black circles; male, open circles). **a-e)** Spearman's rank correlation. Ab, antibody; combined, correlation including both male and female HCW; HCW, health care workers; M, Membrane; ORF, open reading frame; ns, not significant; nAb, neutralising antibody; NP, Nucleoprotein; S1, Spike subunit 1; SFC, spot forming cells per  $10^6$  PBMC; Y, years.

Extended Data Fig. 3



**Extended Data Figure 3. SARS-CoV-2 specific immune responses in HCW with laboratory-confirmed infection by gender and ethnicity:**

**a)** Magnitude of T cell responses to individual SARS-CoV-2 proteins, MEP and OLP pools, Peak S1 IgG Ab titre and nAb titre (IC50) in white and BAME HCW with laboratory-confirmed SARS-CoV-2 infection (n = 76).

**b)** Proportion of white and BAME HCW with laboratory-confirmed SARS-CoV-2 infection who had  $\geq 1$  COVID-19 case definition symptoms (Red), non-case defined symptoms (Blue) or were asymptomatic (Grey) (n = 76).


**c)** Magnitude of T cell responses to individual SARS-CoV-2 proteins, MEP and OLP pools, Peak S1 IgG Ab titre and nAb titre (IC50) in female and male HCW with laboratory-confirmed SARS-CoV-2 infection (n = 76).

**d)** Proportion of female and male HCW with laboratory-confirmed SARS-CoV-2 infection who had  $\geq 1$  COVID-19 case-definition symptoms (Red), non-case-defined symptoms (Blue) or were asymptomatic (Grey) (n = 76).

**a,c)** Mann-Whitney t-test. BAME, Black, Asian and Minority Ethnic; HCW, health care workers; M, Membrane; ORF, open reading frame; nAb, neutralising antibody; NP, Nucleoprotein; S1, Spike subunit 1; SFC, spot forming cells per  $10^6$  PBMC.



Extended Data Fig. 4



## **Extended Data Figure 4. Demographic characteristics of HCW with laboratory-confirmed SARS-CoV-2 infection but no nAb at 16-18 weeks after UK lockdown**

**a)** Neutralisation (%) curves of serum from selected HCW with laboratory-confirmed SARS-CoV-2 infection (red line with red triangles), a positive neutralising control serum (black line with black circles) and a negative non-neutralising control serum (black squares). Example neutralisation curves of participants with high (top row), low (middle row) or no neutralising ability (bottom row) are shown.


**b)** The nAb titre (IC<sub>50</sub>) in HCW with laboratory-confirmed SARS-CoV-2 infection (n = 70). HCW with no neutralising antibody (n = 7) are within the lower blue box.

**c)** The age in years of HCW for whom nAb were detected (top) or were not (bottom).

**d)** Proportion of HCW with nAb (top row), or no nAb (bottom row) stratified by the demographic characteristics of gender, ethnicity, clinical role, clinical location, PPE or symptom profile.

**a)** Bar at geomean. A&E, Accident and Emergency; AHCP, Allied health care professional; AICU, Adult intensive care unit; BAME, Black, Asian and Minority Ethnic; COVID-19 IP, COVID-19 in patient ward; HCW; health care workers; nAb, neutralising antibody; PPE, Personal protective equipment; Y, years.

## Extended Data Fig. 5



**Extended Data Figure 5. Demographic characteristics of health care workers with laboratory-confirmed SARS-CoV-2 infection but no T cell response to Spike or NP protein at 16-18 weeks after UK lockdown:**

**a)** Correlation between peak S1 IgG Ab titre and T cell response to Spike protein in HCW with laboratory-confirmed SARS-CoV-2 infection, coloured by symptom group: HCW who had  $\geq 1$  COVID-19 case definition symptoms (Red), non-case definition symptoms (Blue) or were asymptomatic (Grey). HCW with no T cell response to Spike protein are within the blue box.

**b)** The age in years of HCW for whom a T cell response to Spike protein was detected (top) or was not (bottom).

**c)** Proportion of HCW with a T cell response to Spike protein (top row), or no T cell response to Spike protein (bottom row) stratified by the demographic characteristics of gender, ethnicity, clinical role, clinical location, PPE or symptom profile.


**d)** Correlation between peak S1 IgG Ab titre and T cell response to NP protein in HCW with laboratory-confirmed SARS-CoV-2 infection, coloured by symptom group as above. HCW with no T cell response to NP protein are within the blue box.

**e)** The age in years of HCW for whom a T cell response to NP protein was detected (top) or was not (bottom).

**f)** Proportion of HCW with a T cell response to NP protein (top row), or no T cell response to NP protein (bottom row) stratified by the demographic characteristics of gender, ethnicity, clinical role, clinical location, PPE or symptom profile.

**a, d)** Spearman's rank correlation. A&E, Accident and Emergency; AHCP, Allied health care professional; AICU, Adult intensive care unit; BAME, Black, Asian and Minority Ethnic; COVID-19 IP, COVID-19 in patient ward; PPE, Personal protective equipment; S1, Spike subunit 1; SFC, spot forming cells per  $10^6$  PBMC; Y, years.

Extended Data Fig. 6




## **Extended Data Figure 6. Correlations between antibody and T cell responses in HCW with laboratory-confirmed SARS-CoV-2 infection.**

**a)** Correlations between the peak NP IgG/IgM antibody titre and T cell responses to NP protein (left) and Spike protein (right) in HCW with laboratory-confirmed SARS-CoV-2 infection (n=75)

**b-e)** Top panels; Magnitude of the T cell response to Spike protein (n = 75) **b)** Cumulative magnitude of T cell responses to Spike protein and Spike mapped epitope peptide (MEP and MEP2) pools (n = 70) **c)** NP protein and NP, M and ORF3a/7a MEP pools (n = 75) **d)** or NP1, NP2, M and ORF3a overlapping peptide (OLP) pools (n = 70) **e)** ordered by increasing cumulative magnitude of T cell responses in HCW with laboratory-confirmed SARS-CoV-2 infection. Bottom panels; nAb titres (IC50) in HCW with laboratory-confirmed SARS-CoV-2 infection, ordered by corresponding top panel.

**f)** The number of reactive SARS-CoV-2 proteins or peptide pools (top panel) and nAb titre (IC50; bottom panel) in HCW with laboratory-confirmed SARS-CoV-2 infection (n = 70). Top panel ordered by cumulative magnitude; bottom panel ordered by top panel. HCW with no nAb (IC50 titre less than 50) are indicated by black arrows. + and \* denote two individuals with no T cell response to any protein or peptide pool. **a)** Spearman's rank correlation, least squares log-log lines shown. HCW, health care workers; M, Membrane; nd, not done; nAb; neutralising antibody; NP, Nucleoprotein; ORF, open reading frame; SFC, spot forming cells per 10<sup>6</sup> PBMC.

Extended Data Fig. 7




## **Extended Data Figure 7. T cell responses to SARS-CoV-2 in HCW with laboratory-confirmed infection stratified by symptoms:**

**a)** T cell responses to Spike and NP proteins and to mapped epitope peptide pools (MEP) in HCW with laboratory-confirmed SARS-CoV-2 infection (n = 75) stratified by symptom group:  $\geq 1$  case-definition symptom (Red; n = 48);  $\geq 1$  non-case definition symptom (Blue; n = 19) or asymptomatic (Grey; n = 8) throughout trial and within 3-months of trial initiation.

**b)** T cell responses to Spike MEP2 and overlapping peptide pools (OLP) in HCW with laboratory-confirmed SARS-CoV-2 infection (n = 71) stratified by symptom group:  $\geq 1$  case-definition symptom (Red; n = 45);  $\geq 1$  non-case definition symptom (Blue; n = 19) or asymptomatic (Grey; n = 7) throughout trial and within 3 months of trial initiation. **a,b)** Bars at geomean, Kruskal-Wallis multiple comparison ANOVA with Dunn's correction. HCW, health care workers; M, Membrane; ORF, open reading frame; NP, Nucleoprotein; SFC, spot forming cells per  $10^6$  PBMC).



## Extended Data Fig. 8



### Extended Data Figure 8. Consort flow diagram for the COVIDsortium London healthcare worker cohort and sub-cohort:

CONSORT flow diagram showing participant recruitment into COVIDsortium London healthcare worker study. Participants were stratified by SARS-CoV-2 PCR and antibody laboratory tests and by symptoms experienced during follow-up and during the 3 months prior to study initiation. SARS-CoV-2 laboratory test positive and negative participant sub-cohort groups were matched for gender, age and ethnicity.

**Extended Data Table 1. a, HCW characteristics and COVID-19 status. b, characteristics of pre-pandemic COVID-19 controls.**

**a**

	Total	Laboratory confirmed COVID-19 SARS-CoV-2 PCR* and/or Euroimmun Ab*				SARS-CoV-2 PCR and Euroimmun Ab*		
		i) One or more COVID-19 Case definition symptoms	ii) Non-case definition COVID-19 symptoms	iii) Asymptomatic	iv) All of i)-iii)	One or more COVID-19 case definition symptoms	Non-case definition COVID-19 symptoms	Asymptomatic
Number of HCW, n, (% of total)	136	49 (36)	19 (14)	8 (6)	76 (56)	26 (19)	24 (18)	10 (7)
Mean age (range)	37 (21-62)	42 (21-62)	40 (25-61)	38 (28-62)	41 (21-62)	36 (25-58)	41 (21-62)	39 (24-60)
Gender:								
Female, n (%)	88 (65)	30 (61)	14 (74)	6 (75)	50 (66)	18 (69)	15 (63)	5(50)
Male, n (%)	48 (35)	19 (39)	5 (26)	2 (25)	26 (34)	8 (31)	9 (37)	5 (50)
Ethnicity:								
White, n (%)	98 (72)	34 (69)	14 (74)	7 (88)	55 (72)	16 (62)	19 (79)	8 (80)
BAME, n (%)	38 (28)	15 (31)	5 (26)	1 (12)	21 (28)	10 (38)	5 (21)	2 (20)
Clinical role								
Doctor, n (%)	33 (24)	15 (30)	5 (26)	0 (0)	20 (26)	6 (23)	6 (25)	1 (10)
Nurse, n (%)	48 (35)	16 (33)	5 (26)	4 (50)	25 (33)	11 (42)	9 (37.5)	3 (30)
AHCP, n (%)	55 (41)	18 (37)	9 (48)	4 (50)	31 (41)	9 (35)	9 (37.5)	6 (60)
Clinical location								
AICU/anaesthesia, n, %	17 (12)	7 (14)	2 (10)	0 (0)	9 (12)	4 (15)	4 (17)	0 (0)
Cardiac/A&E, n, %	32 (23)	9 (18)	6 (32)	5 (63)	20 (26)	6 (23)	5 (21)	1 (10)
Other, n, %	73 (54)	28 (58)	9 (48)	3 (37)	40 (53)	14 (54)	14 (58)	5 (50)
Laboratory, n, %	8 (5.5)	3 (6)	0 (0)	0 (0)	3 (4)	0 (0)	1 (4)	4 (40)
COVID-19 IP, n, %	6 (5.5)	2 (4)	2 (10)	0 (0)	4 (5)	2 (8)	0 (0)	0 (0)
PPE								
Yes, n, %	102 (75)	38 (78)	16 (84)	8 (100)	62 (82)	17 (65)	15 (62)	8 (80)
No, n, %	34 (25)	11 (22)	3 (16)	0 (0)	14 (18)	9 (35)	9 (38)	2 (20)
High-risk procedures								
Yes, n (%)	28 (21)	6 (12)	5 (26)	4 (50)	15 (20)	6 (23)	5 (21)	2 (20)
No, n (%)	108 (79)	43 (88)	14 (74)	4 (50)	61 (80)	20 (77)	19 (79)	8 (80)

**b**

	Pre-COVID-19 pandemic controls	
	Cohort 1	Cohort 2
Number of subjects	20	19
Mean age (range)	55 (20-80)	29 (16-39)
Gender:		
Female, n (%)	15 (75)	11 (58)
Male, n (%)	5 (25)	8 (42)
Ethnicity:		
White, n (%)	10 (50)	15 (79)
BAME, n (%)	10 (50)	4 (21)

Abbreviations: A&E, Accident and Emergency; AHCP, Allied health care professional; AICU, Adult intensive care unit; BAME, Black, Asian and Minority Ethnic; COVID-19 IP, COVID-19 in patient ward; PPE, Personal protective equipment

## Extended Data Table 2. a, Mapped epitope peptide (MEP) pools. b, Spike MEP2 pool and overlapping peptides (OLP) pools.

**a**

Protein	Position	AA Sequence
<b>Spike mapped epitope pool (Spike MEP)</b>		
Spike	166-180	CTFEYVSQPFLMDLE
Spike	191-205	EFVFNKIDGVFKIYS
Spike	206-230	KHTPNLVRDLPGQGF
Spike	211-225	NLVRDLPGQGFSALEP
Spike	351-365	YAWNRRKNSCNVADY
Spike	381-395	GVSPTKLNDLGFNTV
Spike	446-460	GGNYWYLRFRKSN
Spike	451-465	YLYRFRKSNLKPFE
Spike	506-520	VVLSFELLHAPATVC
Spike	526-540	GPVKSTNLVKNKCVN
Spike	721-735	SVTTEILPVSMTKTS
Spike	746-760	STECNSLLQYGSFC
Spike	751-765	NLLQLYGSFCTQLNR
Spike	801-815	NFSQILPDPSPKSKR
Spike	866-880	TDEMAIQYSALLAG
Spike	1171-1185	GINASVVNIQKIDR
Spike	1196-1210	LIDLQELGKYEQYI
Spike	1206-1220	YEQYIKWPWYIWLGF
<b>Nucleoprotein mapped epitope pool (NP MEP)</b>		
NP	1-17	MSDNGPQNQRNAPRITF
NP	8-25	NQRNAPRITFGGSDSTG
NP	82-95	DQIYYRATRIR
NP	101-113	MKDLSPRWYFYLL
NP	104-121	LSPRWYFYLLGTGPEAGL
NP	313-330	AFFGMSRIGMEVTPSGTW
NP	321-338	GMEVTPSGTWLTYTGAIK
NP	329-346	TWLYTGAIKLDDKPNF
NP	344-361	PNFKDQVILLNKHIDAYK
NP	352-369	LLNKHIDAYKTFPPTEPK
<b>Membrane mapped epitope pool (M MEP)</b>		
M	133-150	LLESELVIGAVILRGHLR
M	141-158	GAVILRGHLRIAGHHLGR
M	149-166	LRAGHHLRGCDIKDLPK
M	165-181	PKETVATSRILSYK
M	172-188	TSRILSYKLGASQVRA
M	201-218	IGNYKLNTHSSSSDNIA
<b>Open reading frames 3a/7a mapped epitope pool (ORF3a/7a MEP)</b>		
ORF3a	145-160	YFLCWHTNCYDYCIPI
ORF3a	198-215	KDCVWLSYVTSYDYLQY
ORF3a	206-225	YFTSDYQLYVTSYDYLQY
ORF3a	224-243	GVEHVTFYFNKIVDEPEEH
ORF7a	9-25	LITLATCELYHYQECVIR
ORF7a	46-63	FHPLADNKFLCTFSTQF
ORF7a	69-86	DGVKHVVQLRARSVSPKL

**b**

Protein	Position	AA Sequence	Protein	Position	AA Sequence	Protein	Position	AA Sequence	Protein	Position	Amino acid Sequence			
<b>Spike mapped epitope pool 2 (Spike MEP2)</b>														
Spike	101-115	HWGIFGTLDSKSTQ	<b>Nucleoprotein Overlapping peptide pool (NP ORF3a OLP)</b>				<b>Membrane Overlapping peptide pool (M OLP)</b>				<b>Open reading frames 3a overlapping peptide pool (ORF3a OLP)</b>			
Spike	106-120	FGTLLDSKTSQSLIV	NP1	1-15	MSDNGPQNQRNAPR	M	131-145	PLLISELVIGAVIL	ORF3a	1-15	MDLFMFRIFTGIVTFL			
Spike	166-180	CTFEYVSQPFLMDLE	NP1	6-20	FNQRNAPRITFGG	M	136-150	SELVIGAVILRGHLR	ORF3a	6-20	RIFTGIVTLKQGEI			
Spike	171-185	YVQDFEMDLEGRKGN	NP1	11-25	NAPRITFGGSDSTG	M	141-155	GAVILRGHLRIAGH	ORF3a	11-25	GTVTLQGEIKDAP			
Spike	216-230	YFTSDYQLYVTSYDYLQY	NP1	16-30	TFGGSDSTGNSONG	M	146-160	RGHLRIAGHHLRGCD	ORF3a	16-30	KQGEIKDAPSFDFVR			
Spike	241-255	LLAINHRYVLPDSSD	NP1	26-40	SNONGSRSRARSQR	M	151-165	AGHHLRGCDHIDLP	ORF3a	21-35	KDAPSFDFVRATATI			
Spike	246-260	RSYLTGPDSSSGWTA	NP1	31-45	ESGSRKSRKRPQDL	M	156-170	LGCDHIDLPKTEYV	ORF3a	26-40	SDFVRATATIQAIS			
Spike	291-305	CALDRSEKTEKTLKS	NP1	41-55	PNKTSRWFALTQHG	M	166-180	KEITVATSRILSYK	ORF3a	31-45	ATATIQAISLPGFW			
Spike	296-310	LSETEKTSKSTYVEK	NP1	46-60	SWFTALTONKEDLK	M	171-185	ATSRILSYKLGASQ	ORF3a	36-50	PIQASLPGFWLIVGV			
Spike	301-315	SETEKTSKSTYVEK	NP1	51-65	ITQHGKEDLKEPFRQ	M	176-190	LSYKLGASQVRAVGG	ORF3a	41-55	LPFGVILVALVALLV			
Spike	306-320	FVYKGIQTSNFRV	NP1	61-75	KEELKTFGGGVYIN	M	181-195	LGASQVRAVGGFAA	ORF3a	46-60	LIVGVALLVFQASAS			
Spike	311-325	GIWQTSNFRVQPTES	NP1	71-85	GVPIHTNSPDDGIG	M	186-200	RVAGDSGFVAYSYR	ORF3a	51-65	ALLVDFQASAKITL			
Spike	371-385	SASFSTFCYGVSPIT	NP1	76-90	TDKSGDQDQYVRRR	M	191-205	SGFAYSYRGNVYK	ORF3a	56-70	FQASAKITLKRWRQ			
Spike	376-390	YFKCYGVSPPKLNLDL	NP1	81-95	DDQIGYRATRIR	M	196-210	YSRFRIGAKYLNTOH	ORF3a	61-75	KITLKRWRQLKLSK			
Spike	421-435	YNYLPGDSTGCVIA	NP1	86-100	YRRATRRIRGGDQK	M	201-215	IGNYKLNTHSSSSD	ORF3a	66-80	KKRWRQLKLSKGVHFV			
Spike	436-450	WNSNLLDSYGGWYIN	NP1	91-105	TRRIRGGQKRNLSL	M	206-220	LNTHSSSSDNIALL	ORF3a	71-85	LKLSKGVHFVYCNLL			
Spike	441-455	LDKVVGGNYLYLRL	NP1	96-110	GGDQKMLSPRWYF	M	211-225	SSSSDNIALLVQ	ORF3a	76-90	GVHFVGNLHLLFTV			
Spike	446-460	GGNYWYLRFRKSN	NP1	101-115	MKDLSPRWYFYLLGT				ORF3a	81-95	CNLLFTVYVSYHL			
Spike	451-465	YLYRFRKSNLKPFE	NP1	111-121	YLLGTPEALPFGA				ORF3a	86-100	LFTVYVSYHLVVAAG			
Spike	456-470	IRKRLNRYVDFEIST	NP1	106-120	PRWYFYLLGTGPEAGL				ORF3a	91-105	SHYLLVVAAGLEAP			
Spike	461-475	LKPFERDSTFQQA	NP1	116-130	GPAGLPGYKAKDGI				ORF3a	96-110	LVAAAGLEAPLFLYA			
Spike	526-540	GPVKSTNLVKNKCVN	NP1	121-135	LPKGANIDGIHWVAT				ORF3a	101-115	LVLYALVLYFQSLV			
Spike	531-545	TNLVKNKCVNFRNG	NP1	126-140	NKDGIVWVATEGALN				ORF3a	106-120	LVLYALVLYFQSLV			
Spike	541-555	FRNPGITGEGVTFES	NP1	131-145	IVWVATEGALNPKDH				ORF3a	111-125	VYVLYQSLVFNIRH			
Spike	546-560	LITGTVTSNIRKFL	NP1	136-150	EGALNPKDHFRGHRN				ORF3a	116-130	QSNVFNIRHRLWLIC			
Spike	646-660	RAGGLGAEHWNYSYD	NP1	141-155	TPDHISTKRWANNA				ORF3a	121-135	VRIIRMLCWLCKCRS			
Spike	651-665	IGAEHWNYSYD	NP1	146-160	IGTRNPNANAAVLQ				ORF3a	126-140	RWLCLWCKCRSNPIL			
Spike	686-700	SVASGSIYATMSLIG	NP1	151-165	PANNAANVQLQKGT				ORF3a	131-145	WCKCRSNPILVDANY			
Spike	691-705	SYATMSLIGANSYV	NP1	156-170	AVNLQQLPGLTTPG				ORF3a	136-150	KNPILVDANVLCWHL			
Spike	696-710	TRKLSGANDVAYSN	NP1	161-175	LPQGITLPGFPAAG				ORF3a	141-155	YDANYVLCWHTNCYD			
Spike	746-760	STECNSLLQYGSFC	NP1	166-180	TRPGFAGKSGGGG				ORF3a	146-160	FLCWHTNCYDYCIPI			
Spike	751-765	NLLQLYGSFCTQLNR	NP1	171-185	FYAEKSGGSAQSSR				ORF3a	151-165	TNCYDYCIPIYNSVTS			
Spike	776-790	KHTQVFAQVKQYIK	NP1	176-190	SRGGSSASSSSRS				ORF3a	156-170	YCIPIYNSVTSIIVT			
Spike	781-795	VYAGVKQYKTPPKK	NP1	181-195	QASRSRNSRNSR				ORF3a	161-175	NSVTSIIVTSDGDT			
Spike	786-800	KQYTFPFDIGSFT	NP1	186-200	SSRSRNSRNSRSTG				ORF3a	166-180	SNVTSIGDGTSPISF			
Spike	791-805	TPPKDGFQNFSDQI	NP1	191-205	RNSRNSRSTGSDG				ORF3a	171-185	SDGDTSPISFHDYQ			
Spike	801-815	NFSQILPDPSPKSKR	NP1	196-210	NSRSTGSPARMK				ORF3a	176-190	TPSIFHDYQIGGVY			
Spike	831-845	AGFRQYQDCLGDGA	NP1	201-215	SRSTGSPARMAGNG				ORF3a	181-195	EHQYIGGVYKWKES			
Spike	836-850	CYQDCLGDGAARDLI	NP2	206-220	SPARMAGNGDAALA				ORF3a	186-200	IGGVYKWKESGVKDC			
Spike	891-905	GGAGLPRFAMQAMR	NP2	211-225	AGNGDAALLLDD				ORF3a	191-205	EGKESGVKDCVLLHS			
Spike	901-915	QMARFYNGIVGTQNV	NP2	216-230	DALALLLDRNLDD				ORF3a	196-210	GVKDCVLLHSVFTSD			
Spike	906-920	FNGIVGTQNVLYNQ	NP2	221-235	LLDLRNLDRNLDD				ORF3a	201-215	YFTSDYQLYVTSYDYLQY			
Spike	936-950	DSLSSTASALGLQD	NP2	226-240	RILDLRNLDRNLDD				ORF3a	206-220	YFTSDYQLYVTSYDYLQY			
Spike	941-955	TRASLRSRGGDQVFNKN	NP2	231-245	EMSMKSGKQDQDQGT				ORF3a	211-225	YVLYQSLVFNIRH			
Spike	956-970	ADALNTLVKQSLNHF	NP2	236-250	QSGDQDQGTQYTKG				ORF3a	216-230	STQSLDSTGVEHVTF			
Spike	976-990	VINDILSRDLKVEAE	NP2	241-255	QQGQYTKGSAAEAS				ORF3a	221-235	EHVTFYFNKIVDEPEEH			
Spike	996-1010	LITRGLSGLQYVYVQ	NP2	246-260	VTKSAAEASRFRQ				ORF3a	226-240	FVYNKIVDEPEEHQD			
Spike	1011-1025	QLIRAAERASANNA	NP2	251-265	AKASRFRFRATAT				ORF3a	231-245	EHVTFYFNKIVDEPEEH			
Spike	1016-1030	AKIRASAKLAKTKTAS	NP2	256-270	KFRFRATATKAYIN				ORF3a	236-250	IEHVTFYFNKIVDEPEEH			
Spike	1036-1050	APHGVVYVHTVYVPA	NP2	261-275	KRTATKAYINVQARG				ORF3a	241-255	IEHVTFYFNKIVDEPEEH			
Spike	1181-1195	KEIDRLNEAVKLNLE	NP2	266-280	KATYINVQARGHGG				ORF3a	246-260	IHTDVSSTGVMVPM			
Spike	1186-1200	INEAVKLNLESLDL	NP2	271-285	TQARGHGGPEQDQGN				ORF3a	251-265	GGSSVNVPMPEYD			
Spike	1191-1205	IKNRESLQDLELQK	NP2	276-290	RRQPEQDQGNFDQDE				ORF3a	256-270	VNPMPEYDPTTT			
Spike	1216-1230	NWLGFIAGLIVMVM	NP2	281-295	QDQGNFDQDELRGQ				ORF3a	261-275	EPYDPTTTTSPVL			
			NP2	286-300	FDQDELRGQDQYKH									
			NP2	291-305	LRIGDTDYKHWPQIA									
			NP2	296-310	TDYKHWPQIAQAPAS									
			NP2	301-315	WPQIAQAPASAFF									
			NP2	306-320	QAPASAFFGMSRI									
			NP2	311-325	ASAFGMSRMEVETV									
			NP2	316-330	GM SRIGMEVTPSGTW									
			NP2	321-335	GM EVTPSGTWLTYTGAIK									
			NP2	326-340	PSGTLTYTGAIKLDDKPNF									
			NP2	331-345	LYTGAIKLDDKPNF									
			NP2	336-350	AKLDDKPNFQDQV									
			NP2	341-355	QKPNKIDVLLNK									
			NP2	346-360	FDQVLLNKHIDAYK									
			NP2	351-365	ILNKHIDAYKTFPP									
			NP2	356-370	HIDAYKTFPPTEPK									
			NP2	361-375	KTFPPTEPKDKKXK									
			NP2	366-380	TEPKDKKXKADDTQ									
			NP2	371-385	QKDKKXKADDTQALRQ									
			NP2	376-390	ADDTQALRQKQYTKL									
			NP2	381-395	ALRQKQYTKLQYLL									
			NP2	386-400	QKQDQYLLPAPADL									
			NP2	391-405	VYLLPAPADLDFQSL									
			NP2	396-410	PAPADLDFQSLQDLS									
			NP2	401-415	DFQSLQDLSGMSASD									
			NP2	406-420	QLDLSGMSASDSTDA									